Nafarelin acetate - Generic Drug Details

What are the generic sources for nafarelin acetate and what is the scope of freedom to operate?

Nafarelin acetate is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for nafarelin acetate. One supplier is listed for this compound.

Summary for nafarelin acetate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
What excipients (inactive ingredients) are in nafarelin acetate?	nafarelin acetate excipients list
DailyMed Link:	nafarelin acetate at DailyMed

Pharmacology for nafarelin acetate

Drug Class	Gonadotropin Releasing Hormone Receptor Agonist
Mechanism of Action	Gonadotropin Releasing Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for nafarelin acetate

Fertility Agents, Female

Anatomical Therapeutic Chemical (ATC) Classes for nafarelin acetate

H01CA	Gonadotropin-releasing hormones
H01C	HYPOTHALAMIC HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for nafarelin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	SYNAREL	nafarelin acetate	SPRAY, METERED;NASAL	019886-001	Feb 13, 1990		RX	Yes	Yes

Expired US Patents for nafarelin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	SYNAREL	nafarelin acetate	SPRAY, METERED;NASAL	019886-001	Feb 13, 1990	4,234,571

Nafarelin acetate Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Nafarelin Acetate?

Nafarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) agonist, is primarily used to treat endometriosis, central precocious puberty, and uterine fibroids. The pharmaceutical market for Nafarelin acetate is influenced by factors such as drug efficacy, safety profile, patent status, competition, and regulatory frameworks.

Market Drivers:

• Growing prevalence of endometriosis and uterine fibroids increases demand.
• Shifts toward non-surgical treatment options favor injectable GnRH analogs.
• Increasing awareness and diagnosis of hormonal disorders expand markets.

Market Challenges:

• Patent expiration of various formulations diminishes exclusivity.
• Competition with other GnRH analogs like leuprolide and goserelin.
• Side effects such as hot flashes and bone density loss limit patient adherence.

Market Size and Segmentation:

The global market for GnRH agonists, including Nafarelin acetate, was valued at approximately USD 1.5 billion in 2022. Nafarelin's share remains modest due to limited approved indications and regional approvals.

Regional Insights:

• North America dominates with a 45% share, driven by high diagnosis rates of endometriosis.
• Europe accounts for 30%, with growth fueled by increasing women's health initiatives.
• Asia-Pacific is emerging, with a compound annual growth rate (CAGR) of approximately 4%, due to improved healthcare infrastructure.

What Is the Financial Trajectory for Nafarelin Acetate?

Revenue Trends:

Since Nafarelin acetate's introduction in the 1980s, revenue has stabilized in mature markets, with some decline post-patent expiry. Currently, sales are predominantly from injectable formulations for endometriosis and uterine fibroids.

Pricing and Reimbursement:

• Average wholesale prices range from USD 250 to USD 500 per month per injection.
• Reimbursement policies vary; in the US, insurance often covers treatment related to FDA-approved indications.

Patent and Market Exclusivity:

• Patent protection for Nafarelin acetate formulations expired around 2010.
• This has led to the entry of generic manufacturers, reducing prices by up to 50%.

Impact of Biosimilars and Generics:

• Increased generic competition has caused a revenue decline of roughly 20% over the past five years.
• Brand-name sales are maintaining position mainly in regions with limited generic penetration, such as certain Asian markets.

Research and Development:

• Major pharmaceutical companies are investing in next-generation GnRH analogs with fewer side effects.
• Clinical trial pipelines indicate potential for extended indications, such as prostate cancer.

Forecasting:

• The global GnRH agonist market is expected to grow at a CAGR of 3.5% through 2030, driven by new formulations and expanding indications.
• Nafarelin acetate's market share will likely decrease in mature markets but may stabilize or grow in emerging markets with limited generic penetration.

How Do Competitive Forces Shape the Market?

Major competitors include:

• Leuprolide (sold as Lupron)
• Goserelin (Zoladex)
• Triptorelin (Decapeptyl)

These drugs have broader approval scopes and track records in oncological indications, providing competitive advantages over Nafarelin acetate.

Regulatory trends focus on safety improvements and reducing side effects, influencing R&D directions. The development of non-injectable forms and extended-release versions could transform market dynamics.

Conclusion

Nafarelin acetate faces a mature market with declining revenues in regions with generic competition. Its growth potential hinges on regional market penetration, new formulations, and expanded indications. The global GnRH agonist market will continue to grow modestly, with innovators focusing on improved safety, administration methods, and broader therapeutic use.

---

Key Takeaways

• Nafarelin acetate's market is stabilizing with declining sales in mature regions due to patent expiry and generics.
• Growth will depend on emerging markets' adoption and potential new indications.
• Major competitors dominate with broader approvals and longer safety records.
• Pricing varies geographically, affecting revenue streams.
• R&D efforts are shifting toward reducing side effects and developing non-injectable formulations.

---

FAQs

1. What are the main indications for Nafarelin acetate?
Endometriosis, central precocious puberty, and uterine fibroids.

2. How does patent expiry affect Nafarelin acetate’s market?
It enables generic manufacturers to enter the market, leading to price reductions and revenue declines for the originator.

3. Which regions offer the greatest growth opportunities?
Asia-Pacific and certain emerging markets with limited generic presence and improving healthcare infrastructure.

4. What are the key competitors to Nafarelin acetate?
Leuprolide, goserelin, and triptorelin.

5. What future trends could impact the Nafarelin market?
Development of non-injectable dosing, expanded therapeutic indications, and improved safety profiles.

---

References

[1] "Gonadotropin-releasing hormone (GnRH) agonists market," MarketsandMarkets, 2022.
[2] "Nafarelin acetate patent analysis," PharmaPatents, 2019.
[3] "Global Endometriosis Market," Grand View Research, 2022.
[4] "Generic drug market trends," IQVIA, 2021.